Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 3, 2022

View Archived Issues

Tyrosine kinase inhibitor NTRC-0652-0 shows promise for the treatment of cholangiocarcinoma

New prolyl endopeptidase inhibitors identified at Accure Therapeutics

ReViral describes new compounds for respiratory syncytial virus infections

Mcl-1 inhibitors discovered at Janssen

3M Innovative Properties divulges new Toll-like receptor 7 agonists

Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical patent Bcl-2 and/or Bcl-X inhibitors

Endothelial BCAR1 expression associated with antiangiogenic therapy resistance

Discovery of novel MBL inhibitors as promising beta-lactam antibiotics

Epigenetic-mediated immune mechanisms identified in TB

A microbiota-macrophage-iron axis regulates hematopoietic stem cell fate decisions under stress

A comprehensive catalog of functional cell types and cellular states in human brain metastases

Targeting PPARalpha-ACOT12 axis as a potential new therapeutic strategy for osteoarthritis

PLA2-IIA modulates immunity through its interaction with microbiota

CIRM grant supports Juvena's preclinical work on JUV-161 for myotonic dystrophy type 1

Brickell licenses rights to Carna's STING antagonists for autoimmune and inflammatory diseases

Anakuria's AT-20494 to be studied for ADPKD and other indications

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...